Practical implications for the administration of 13-cis retinoic acid in pediatric oncology
- Author
- Tieneke Bauters (UGent) , Veronique Van De Velde (UGent) , Yves Benoit, Hugo Robays (UGent) and Genevieve Laureys (UGent)
- Organization
- Abstract
- Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.
- Keywords
- HIGH-RISK NEUROBLASTOMA, 13-CIS-RETINOIC ACID, Pediatric oncology, 13-cis retinoic acid, Clinical pharmacy, ISOTRETINOIN, CHILDREN, ACNE
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 130.28 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-1256134
- MLA
- Bauters, Tieneke, et al. “Practical Implications for the Administration of 13-Cis Retinoic Acid in Pediatric Oncology.” INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol. 33, no. 4, 2011, pp. 597–98, doi:10.1007/s11096-011-9519-9.
- APA
- Bauters, T., Van De Velde, V., Benoit, Y., Robays, H., & Laureys, G. (2011). Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. https://doi.org/10.1007/s11096-011-9519-9
- Chicago author-date
- Bauters, Tieneke, Veronique Van De Velde, Yves Benoit, Hugo Robays, and Genevieve Laureys. 2011. “Practical Implications for the Administration of 13-Cis Retinoic Acid in Pediatric Oncology.” INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. https://doi.org/10.1007/s11096-011-9519-9.
- Chicago author-date (all authors)
- Bauters, Tieneke, Veronique Van De Velde, Yves Benoit, Hugo Robays, and Genevieve Laureys. 2011. “Practical Implications for the Administration of 13-Cis Retinoic Acid in Pediatric Oncology.” INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. doi:10.1007/s11096-011-9519-9.
- Vancouver
- 1.Bauters T, Van De Velde V, Benoit Y, Robays H, Laureys G. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Vol. 33, INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2011. p. 597–8.
- IEEE
- [1]T. Bauters, V. Van De Velde, Y. Benoit, H. Robays, and G. Laureys, “Practical implications for the administration of 13-cis retinoic acid in pediatric oncology,” INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol. 33, no. 4. pp. 597–598, 2011.
@misc{1256134,
abstract = {{Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.}},
author = {{Bauters, Tieneke and Van De Velde, Veronique and Benoit, Yves and Robays, Hugo and Laureys, Genevieve}},
issn = {{2210-7703}},
keywords = {{HIGH-RISK NEUROBLASTOMA,13-CIS-RETINOIC ACID,Pediatric oncology,13-cis retinoic acid,Clinical pharmacy,ISOTRETINOIN,CHILDREN,ACNE}},
language = {{eng}},
number = {{4}},
pages = {{597--598}},
series = {{INTERNATIONAL JOURNAL OF CLINICAL PHARMACY}},
title = {{Practical implications for the administration of 13-cis retinoic acid in pediatric oncology}},
url = {{http://doi.org/10.1007/s11096-011-9519-9}},
volume = {{33}},
year = {{2011}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: